Drug updated on 11/1/2024
| Dosage Form | Suspension (topical; 0.9%) |
| Drug Class | Pediculicides |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indiacted for the topical treatment of head lice infestations in adult and pediattic patients 6 months of age and older
- Indicated for the topical treatment of scabies infestations in adult and pediatric 4 years of age older.
Latest News
Summary
- This summary is based on the review of one randomized controlled trial(s). [1]
- Primary Efficacy Outcome: At day 28, spinosad 0.9% achieved a complete cure rate of 78.1%, significantly higher than the 39.6% cure rate observed with the vehicle (P < .0001).
- Additional Efficacy Outcomes: Consistent treatment effects were noted for spinosad 0.9% across clinical cure, microscopic cure, and lesion counts, though specific numerical results for these outcomes are not provided.
- Population: Study subjects included individuals aged 4 years or older, with no significant differences observed across subgroups.
- No safety signals were observed during the studies, and no specific safety concerns or adverse effects were reported.
- The studies used small sample sizes, which could limit the robustness of safety findings.
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Natroba (spinosad) Prescribing Information. | 2021 | ParaPRO, LLC, Carmel, IN |
Randomized Controlled Trials
| Document Title | Sex Distribution | Year | Source |
|---|---|---|---|
| Spinosad at 0.9% in the treatment of scabies: Efficacy results from 2 multicenter, randomized, double-blind, vehicle-controlled studies | 206Subjects F: 57% M: 43% | 2022 | Journal of the American Academy of Dermatology |
Sex Distribution:
F:57%
M:43%
206Subjects
Year:
2022
Source:Journal of the American Academy of Dermatology